Lidocaine inhalation - Corus Pharma

Drug Profile

Lidocaine inhalation - Corus Pharma

Alternative Names: Corus 1030

Latest Information Update: 25 Aug 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayo Clinic
  • Developer Corus Pharma
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 24 Sep 2013 Biomarkers information updated
  • 15 Aug 2006 Corus Pharma has been acquired by Gilead Sciences
  • 14 Mar 2006 Discontinued - Phase-II for Asthma in Germany (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top